{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:12:08Z","timestamp":1778663528272,"version":"3.51.4"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T00:00:00Z","timestamp":1463529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI098472"],"award-info":[{"award-number":["RO1 AI098472"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI123024"],"award-info":[{"award-number":["RO1 AI123024"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0155887","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T13:51:22Z","timestamp":1463579482000},"page":"e0155887","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis"],"prefix":"10.1371","volume":"11","author":[{"given":"Roy","family":"Gerona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron T.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Koss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bacchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,5,18]]},"reference":[{"key":"ref1","unstructured":"World Health Organization. Global tuberculosis report 2015. Available at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/tb\/publications\/global_report\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/tb\/publications\/global_report\/en\/<\/ext-link>. Accessed on January 6, 2016."},{"key":"ref2","first-page":"808","article-title":"A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa","volume":"373","author":"TAS Group","year":"2015"},{"key":"ref3","unstructured":"Hosseinipour M, Bisson G, Miyahara S, Sun X, Moses A, Riviere C, et al. Empiric TB therapy does not decrease early mortality compared to isoniazid preventive therapy in adults with advanced HIV initiating ART: results of ACTG A5274 (REMEMBER study). 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), Vancouver, Canada, 19\u201322 July 2015 (abstract MOAB0205LB)."},{"key":"ref4","first-page":"1951","article-title":"Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability","volume":"204","author":"S Srivastava","year":"2011"},{"key":"ref5","first-page":"178","article-title":"Editorial commentary: pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance","volume":"55","author":"EF Egelund","year":"2012"},{"key":"ref6","first-page":"2169","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis","volume":"62","author":"CA Peloquin","year":"2002"},{"key":"ref7","first-page":"1377","article-title":"HIV-associated tuberculosis: clinical update","volume":"50","author":"S Swaminathan","year":"2010"},{"key":"ref8","first-page":"503","article-title":"Adherence to Anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia","volume":"8","author":"G Tesfahuneygn","year":"2015"},{"key":"ref9","first-page":"19585","article-title":"Low isoniazid and rifampicin concentrations in TB\/HIV co-infected patients in Uganda","volume":"17","author":"CS Wiltshire","year":"2014"},{"key":"ref10","first-page":"1685","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"S Chideya","year":"2009"},{"key":"ref11","first-page":"1765","article-title":"Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs","volume":"205","author":"JW Alffenaar","year":"2012"},{"key":"ref12","first-page":"327","article-title":"Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls","volume":"31","author":"PM Edelbroek","year":"2009"},{"key":"ref13","first-page":"353","article-title":"Hair as a biological specimen for therapeutic drug monitoring","volume":"55","author":"J Beumer","year":"2001"},{"key":"ref14","first-page":"696","article-title":"Hair it is: the long and short of monitoring antiretroviral treatment","volume":"137","author":"M Gandhi","year":"2002"},{"key":"ref15","first-page":"471","article-title":"Protease inhibitor levels in hair strongly predict virologic response to treatment","volume":"23","author":"M Gandhi","year":"2009"},{"key":"ref16","first-page":"1267","article-title":"Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy","volume":"52","author":"M Gandhi","year":"2011"},{"key":"ref17","first-page":"333","article-title":"Low lopinavir plasma or hair concentrations explain second line protease inhibitor failures in a resource-limited setting","volume":"56","author":"GU van Zyl","year":"2011"},{"key":"ref18","first-page":"e0129100","article-title":"Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients","volume":"10","author":"SM Baxi","year":"2015"},{"key":"ref19","first-page":"578","article-title":"Hair and Plasma Data Show That Lopinavir, Ritonavir, and Efavirenz All Transfer From Mother to Infant In Utero, But Only Efavirenz Transfers via Breastfeeding","volume":"63","author":"M Gandhi","year":"2013"},{"key":"ref20","first-page":"1453","article-title":"A single-nucleotide polymorphism in CYP2B6 leads to &gt;3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women","volume":"206","author":"M Gandhi","year":"2012"},{"key":"ref21","first-page":"e83736","article-title":"Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP)","volume":"9","author":"AY Liu","year":"2014"},{"key":"ref22","first-page":"311","article-title":"Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya","volume":"66","author":"MD Hickey","year":"2014"},{"key":"ref23","first-page":"825","article-title":"Hair Concentrations of Antiretrovirals Predict Viral Suppression in HIV-Infected Pregnant and Breastfeeding Ugandan Women","volume":"29","author":"C Koss","year":"2015"},{"key":"ref24","first-page":"1009","article-title":"Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children","volume":"31","author":"W Prasitsuebsai","year":"2015"},{"key":"ref25","first-page":"25","article-title":"Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings","volume":"30","author":"M Gandhi","year":"2014"},{"key":"ref26","first-page":"1402","article-title":"Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring","volume":"212","author":"M Gandhi","year":"2015"},{"key":"ref27","first-page":"327027","article-title":"Hair Analysis for Determination of Isoniazid Concentrations and Acetylator Phenotype during Antituberculous Treatment","volume":"2012","author":"M Eisenhut","year":"2012"},{"key":"ref28","first-page":"2591","article-title":"A liquid chromatography\/tandem mass spectrometry method for the simultaneous quantification of isoniazid and ethambutol in human plasma","volume":"19","author":"X Chen","year":"2005"},{"key":"ref29","first-page":"285","article-title":"Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma","volume":"877","author":"L Huang","year":"2009"},{"key":"ref30","first-page":"1331","article-title":"Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography\/tandem mass spectrometry","volume":"21","author":"SH Song","year":"2007"},{"key":"ref31","first-page":"9","article-title":"Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry","volume":"102","author":"HJ Kim","year":"2015"},{"key":"ref32","first-page":"479","article-title":"Clinical pharmacology quality assurance for HIV and related infectious diseases research","volume":"93","author":"R DiFrancesco","year":"2013"},{"key":"ref33","unstructured":"FDA. Guidance for Industry Bioanalytical Method Validation. 2013. Found at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM368107.pdf\" xlink:type=\"simple\">http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM368107.pdf<\/ext-link>"},{"key":"ref34","first-page":"633","article-title":"The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid","volume":"63","author":"PR Donald","year":"2007"},{"key":"ref35","first-page":"1341","article-title":"Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine","volume":"167","author":"M Weiner","year":"2003"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0155887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T22:53:03Z","timestamp":1540335183000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0155887"}},"subtitle":[],"editor":[{"given":"Mark Patrick","family":"Nicol","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,18]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0155887","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,18]]}}}